June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Intravitreal Ziv-Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • Joao Rafael de Oliveira Dias
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Camilla Oliveira Xavier
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Eduardo Amorim Novais
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • André Maia
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Nilva Moraes
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Michel Eid Farah
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Eduardo Büchele Rodrigues
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships Joao Dias, None; Camilla Oliveira Xavier, None; Eduardo Novais, None; André Maia, None; Nilva Moraes, None; Michel Eid Farah, None; Eduardo Büchele Rodrigues, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2300. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joao Rafael de Oliveira Dias, Camilla Oliveira Xavier, Eduardo Amorim Novais, André Maia, Nilva Moraes, Michel Eid Farah, Eduardo Büchele Rodrigues; Intravitreal Ziv-Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2300. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To describe the outcomes of patients with exudative age-related macular degeneration (AMD) that received intravitreal injections of ziv-aflibercept.

Methods: This study was designed to evaluate the retinal safety of intravitreal ziv-aflibercept. Patients with exudative AMD refractory to bevacizumab and treatment-naive patients were included. After approval by the Ethics Committee of the Federal University of São Paulo (IRB number 707.034), Brazil, and signature of the informed consent form, all patients were examined through a complete ophthalmological exam, ETDRS best-corrected visual acuity (BCVA), color fundus image, fluorescein angiogram (FA), optical coherence tomography (OCT), microperimetry and multifocal and full-field electroretinography (ERG). An intravitreal injection of ziv-aflibercept (0.1 mL, 25 mg/mL, total 2.5 mg), under sterile conditions, was performed. After three monthly injections (induction), patients were examined monthly, and subsequent injections were performed as needed (pro re nata). Patients with choroidal neovascularization in both eyes were excluded. Visual acuity, OCT and microperimetry were performed monthly, color fundus image and FA every 6 months, and full-field and multifocal ERG at baseline, 1 and 3 months. Each patient was required to return every 4 weeks for evaluation.

Results: Our research group performed intravitreal injections of ziv-aflibercept in patients with recalcitrant fluid despite many bevacizumab injections, and in treatment-naive patients. At presentation, all patients demonstrated subretinal fluid or cystic spaces in OCT, associated or not with proteinaceous exudates with fibrin deposition. A response was noticed after the initial injection in all patients and a somewhat greater response was seen after the following injections. All patients experienced improvement in the BCVA and in the microperimetric fixation targets, when baseline and follow-up was compared. Mean rod and maximal responses were higher when compared to baseline. No adverse events were reported.

Conclusions: This case series showed that intravitreal ziv-aflibercept was safe to our patients' retinas and could be a cost-effective option for patients which AMD. However, more patients are needed to confirm the retinal safety and efficacy of intravitreal ziv-aflibercept.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×